Therapeutic strategies for targeting cancer stem cells

Abstract

The therapeutic limitations of conventional chemotherapeutic drugs present a challenge for cancer therapy; these shortcomings are largely attributed to the ability of cancer cells to repopulate and metastasize after initial therapies. Compelling evidence suggests that cancer stem cells (CSCs) have a crucial impact in current shortcomings of cancer therapy because they are largely responsible for tumor initiation, relapse, metastasis, and chemo-resistance. Thus, a better understanding of the properties and mechanisms underlying CSC resistance to treatments is necessary to improve patient outcomes and survival rates. In this review, the authors characterize and compare different CSC-specific biomarkers that are present in various types of tumors. We further discuss multiple targeting approaches currently in preclinical or clinical testing that show great potential for targeting CSCs. This review discusses numerous strategies to eliminate CSCs by targeting surface biomarkers, regulating CSC-associated oncogenes and signaling pathways, inhibiting drug-efflux pumps involved in drug resistance, modulating the tumor microenvironment and immune system, and applying drug combination therapy using nanomedicine.

Keywords

Cancer stem cells / targeted cancer therapy / drug resistance

References

[1] Bonnet D.J. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell..Nat Med1997;3:730-7

[2] Al-Hajj M,Benito-Hernandez A,Clarke M.Prospective identification of tumorigenic breast cancer cells..PNAS2003;100:3983-8 PMCID:PMC153034

[3] Singh SK,Terasaki M,Hawkins C,Dirks PB.Identification of a cancer stem cell in human brain tumors..Cancer Res2003;63:5821-8

[4] Kim CF,Woolfenden AE,Babar I,Crowley D,Jacks T.Identification of bronchioalveolar stem cells in normal lung and lung cancer..Cell2005;121:823-35

[5] Beck B.Unravelling cancer stem cell potential..Nat Rev Cancer2013;13:727-38

[6] Chen K,Chen JL.Understanding and targeting cancer stem cells: therapeutic implications and challenges..Acta Pharmacol Sin2013;34:732-40 PMCID:PMC3674516

[7] Wang J,Rich JN.Notch signaling in cancer stem cells..Adv Exp Med Biol2012;727:174-85

[8] Hambardzumyan D1,Rosenblum MK,Manova-Todorova K.PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo..Genes Dev2008;22:436-48 PMCID:PMC2238666

[9] Campbell V.Hedgehog signaling in cancer stem cells: a focus on hematological cancers..Stem Cells Cloning2015;8:27-38

[10] Simões BM,Eyre R,Yu L,Alférez DG,Santiago-Gómez A,Acar A,Howell A,Rydén L,Andó S,Ucar A,Marangoni E,Landberg G,Clarke RB.Anti-estrogen resistance in human breast tumors is driven by JAG1-NOTCH4-dependent cancer stem cell activity..Cell Rep2015;12:1968-77 PMCID:PMC4594158

[11] Bleau AM,Ozawa T,Huse JT,Holland EC.PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells..Cell Stem Cell2009;4:226-35

[12] Bautch VL.Stem cells and the vasculature..Nat Med2011;17:1437-43

[13] Price JE,Zhang RD.Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice..Cancer Res1990;50:717-21

[14] Minn AJ,Siegel PM,Shu W,Viale A,Gerald WL.Genes that mediate breast cancer metastasis to lung..Nature2005;436:518-24 PMCID:PMC1283098

[15] Allahverdiyev AM,Oztel ON,Abamor ES,Ates SC,Baydar SY.Aldehyde Dehydrogenase: Cancer and Stem Cells..In: Canuto RA, editor.2012;Dehydrogenases. InTechRijeka, Croatia3-28

[16] Duan JJ,Xu SL,Ye XZ,Zhang X,Yu SC.Strategies for isolating and enriching cancer stem cells: well begun is half done..Stem Cells Dev2013;22:2221-39 PMCID:PMC3730373

[17] Sheridan C,Fuchs RK,Bhat-Nakshatri P,Goulet RJr,Nakshatri H.CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis..Breast Cancer Res2006;8:R59

[18] Klonisch T,Hombach-Klonisch S,Wesselborg S,Los M.Cancer stem cell markers in common cancers - therapeutic implications..Trends Mol Med2008;10:450-60

[19] Ali HR,Blows FM,Pharoah PD.Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance..Breast Cancer Res2011;6:R118

[20] Tirino V,Paino F,Papaccio F,Laino L,Papaccio G.Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization..FASEB J2013;1:13-24

[21] Greve B,Spaniol K,Götte M.Flow cytometry in cancer stem cell analysis and separation..Cytometry A2012;4:284-93

[22] Komuro H,Shinya M,Kaneko S,Hayashi Y.Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines..J Pediatr Surg2007;42:2040-5

[23] Miranda-Lorenzo I,Lonardo E,Serrano AG,Cioffi M,Zagorac S,Hidalgo M,Kleeff J,Sainz BJr.Intracellular autofluorescence: a biomarker for epithelial cancer stem cells..Nat Methods2014;11:1161-9

[24] Cao L,Zhai B,Xu W,Li J,Chen L,Wu M.Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines..BMC Gastroenterol2011;11:71 PMCID:PMC3136412

[25] Wang K,Wang J.Cancer stem cell theory: therapeutic implications for nanomedicine..Int J Nanomedicine2013;8:899-908

[26] Smalley M,Clarkson R.Breast cancer stem cells: obstacles to therapy..Cancer Lett2013;338:57-62

[27] Suman S,Damodaran C.Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells..Br J Cancer2013;109:2587-96 PMCID:PMC3833225

[28] Zang S,Dai J,Tse W,Ma D.RNAi-mediated knockdown of Notch-1 leads to cell growth inhibition and enhanced chemosensitivity in human breast cancer..Oncol Rep2010;23893-9

[29] Gupta S,Lorusso P.Targeting the Hedgehog pathway in cancer..Ther Adv Med Oncol2010;2:237-50 PMCID:PMC3126020

[30] Zhao C,Jamieson CH,Abrahamsson A,Kwon HY,Chute JP,Munchhof M,Beachy PA.Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia..Nature2009;458:776-9 PMCID:PMC2946231

[31] Berman DM,Hallahan AR,Eberhart CG,Chen JK,Taipale J,Beachy PA.Medulloblastoma growth inhibition by hedgehog pathway blockade..Science2002;297:1559-61

[32] Thayer SP,Heiser PW,Roberts DJ,Qi YP,Fernández-del Castillo C,Antoniu B,Warshaw AL.Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis..Nature2003;425:851-6 PMCID:PMC3688051

[33] Zeilstra J,Dokter M,Spaargaren M.Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis..Cancer Res2008;68:3655-61

[34] Hallett RM,Giacomelli AO,Girgis-Gabardo A,Hassell JA.Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer..PLoS One2012;7:e33976

[35] Gu W,McMillan N.Silencing oncogene expression in cervical cancer stem-like cells inhibits their cell growth and self-renewal ability..Cancer Gene Ther2011;18:897-905

[36] Puca F,Federico A,Tosti N,Del Vecchio L,Battista S.HMGA1 silencing restores normal stem cell characteristics in colon cancer stem cells by increasing p53 levels..Oncotarget2014;5:3234-45 PMCID:PMC4102806

[37] Wang T,Xiang D,Bruce M,Khasraw M,Wang L,AlShamaileh H,She X,Kong L,Duan W.EpCAM aptamer-mediated survivin silencing sensitized cancer stem cells to doxorubicin in a breast cancer model..Theranostics2015;5:1456-72 PMCID:PMC4672025

[38] Deonarain MP,Epenetos AA.Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?.MAbs2009;1:12-25

[39] Zinzi L,Cantore M,Leopoldo M.ABC transporters in CSCs membranes as a novel target for treating tumor relapse..Front Pharmacol2014;5:163 PMCID:PMC4091306

[40] Morrison R,Sun Y,Kim S,Chung CH.Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis..J Oncol2011;2011:941876 PMCID:PMC2958340

[41] Vaz AP,Batra SK.Cancer stem cells and therapeutic targets: an emerging field for cancer treatment..Drug Deliv Transl Res2013;3:113-20 PMCID:PMC3784304

[42] Ding PR,Ohnuma S,An X,Lu QS,Yang DH,Ambudkar SV.The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter..PLoS One2011;6:e19329

[43] Calcagno AM,Gillet JP,Fostel JM,Gottesman MM,Ambudkar SV.Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics..J Natl Cancer Inst2010;102:1637-52 PMCID:PMC2970576

[44] Dönmez Y.Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells..Biomed Pharmacother2011;65:85-9

[45] Li X,Zhang Y,Chen X,Liu Y.Novel Mixed Polymeric Micelles for Enhancing Delivery of Anticancer Drug and Overcoming Multidrug Resistance in Tumor Cell Lines Simultaneously..Pharm Res2010;27:1498-511

[46] Šubr V,Sivák L,Kovář M.Polymer inhibitors of ABC transporter overcoming multidrug resistance: Synthesis, characterization and in vitro evaluation..J Control Release2015;213:e107-8

[47] Falasca M.Investigaional ABC transporter inhibitors..Expert Opin Investig Drugs2012;21:657-66

[48] Schatton T.Antitumor immunity and cancer stem cells..Ann N Y Acad Sci2009;1176:154-69 PMCID:PMC2893543

[49] Lee PP,Savage PA,Brockstedt D,Johnson D,Thompson J,Roederer M.Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients..Nat Med1999;5:677-85

[50] Khong HT,Rosenberg SA.Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression..J Immunother2004;27:184-90 PMCID:PMC2275330

[51] Ames E,Grossenbacher SK,Chen M,Hagino T,Sckisel GD,Monjazeb AM,Sayers TJ.NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype..J Immunol2015;195:4010-9 PMCID:PMC4781667

[52] Ahmadzadeh M.IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients..Blood2006;107:2409-14 PMCID:PMC1473973

[53] Rosenberg SA,Topalian SL,Weber JS,Seipp CA,White DE.Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2..JAMA1994;271:907-13

[54] Rosenberg SA,Spiess PJ,Schwarz SL.Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2..J Exp Med1985;161:1169-88

[55] Itoh K,Balch CM.Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor..J Exp Med1988;168:1419-41

[56] Powell DJJr,Allen T,Rosenberg SA.Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy..J Immunother2007;30:438-47 PMCID:PMC2140222

[57] Canter RJ,Ames E.Immune targeting of cancer stem cells in gastrointestinal oncology..J Gastrointest Oncol2016;7 Suppl 1:S1-10

[58] Deng Z,Ma W,Zhang YQ.Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM..BMC Immunol2015;16:1 PMCID:PMC4318439

[59] Zhu X,Gaedicke S,Firat E.Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57..Oncotarget2015;6:171-84 PMCID:PMC4381586

[60] Schmidt P,Hombach A,Mauch C.Eradication of melanomas by targeted elimination of a minor subset of tumor cells..Proc Natl Acad Sci U S A2011;108:2474-9 PMCID:PMC3038763

[61] Beard RE,Lagisetty KH,Tran E,Abate-Daga D,Fine HA,Rosenberg SA.Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells..J Immunother Cancer2014;2:25 PMCID:PMC4155770

[62] Morgan RA,Davis JL,Woolard KD,Feldman SA,Kuan CT,Zhang W,Rosenberg SA.Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma..Hum Gene Ther2012;23:1043-53 PMCID:PMC3472555

[63] Dong H,Salomao DR,Hirano F,Roche PC,Zhu G,Lennon VA,Chen L.Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion..Nat Med2002;8:793-800

[64] Riley JL,Kobayashi S,Burchard J,Gregson BP,Linsley PS.Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors..Proc Natl Acad Sci U S A2002;99:11790-5 PMCID:PMC129347

[65] Rabinovich GA,Sotomayor EM.Immunosuppressive strategies that are mediated by tumor cells..Annu Rev Immunol2007;25:267-96 PMCID:PMC2895922

[66] Wing K,Prieto-Martin P,Miyara M,Nomura T.CTLA-4 control over Foxp3+ regulatory T cell function..Science2008;322:271-5

[67] Tarhini AA.CTLA-4 blockade: therapeutic potential in cancer treatments..Onco Targets Ther2010;3:15-25

[68] Hu Y.Targeting cancer stem cells: a new therapy to cure cancer patients..Am J Cancer Res2012;2:340-56

[69] Hodi FS,McDermott DF,Sosman JA,Gonzalez R,Schadendorf D,Akerley W,Lutzky J,Vaubel JM,Hogg D,Lebbé C,Quirt I,Wolchok JD,Tian J,Nichol GM,Urba WJ.Improved survival with ipilimumab in patients with metastatic melanoma..N Engl J Med2010;363:711-23 PMCID:PMC3549297

[70] Fong L.Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment..J Clin Oncol2008;26:5275-83

[71] Langer LF,Morse MA.Update on anti-CTLA-4 antibodies in clinical trials..Expert Opin Biol Ther2007;7:1245-56

[72] Hirano F,Tamura H,Wang S,Rietz C,Lau JS,Tamada K.Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity..Cancer Res2005;65:1089-96

[73] Chemnitz JM,Nichols KE,Riley JL.SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation..J Immunol2004;173:945-54

[74] FDA approves new, targeted treatment for bladder cancer: Tecentriq is the first PD-L1 inhibitor approved by the FDA. Food and Drug Administration, FDA News Release 2016

[75] Kawasaki BT.Cancer Stem Cells, CD200 and Immunoevasion..Trends Immunol2008;29:464-8

[76] Kawasaki BT,Hurt EM,Farrar WL.Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells..Biochem Biophys Res Commun2007;364:778-82 PMCID:PMC2168034

[77] Jung YS,Vermeer DW,Goh AR,Lee JH.CD200: association with cancer stem cell features and response to chemoradiation in head and neck squamous cell carcinoma..Head Neck2015;37:327-35 PMCID:PMC4557697

[78] McWhirter JR,Saven A,Potter KN,Ravey EP,Bowdish KS.Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation..Proc Natl Acad Sci U S A2006;103:1041-6 PMCID:PMC1327729

[79] Gorczynski RM,Hu J,Lei J.Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice..Clin Exp Immunol2001;126:220-9 PMCID:PMC1906195

[80] Siva A,Qin F,Bowdish KS.Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200..Cancer Immunol Immunother2008;57:987-96

[81] Korkaya H,Wicha MS.Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots..Clin Cancer Res2011;17:6125-9 PMCID:PMC3312242

[82] Persano L,Basso G.Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting..Biochem Pharmacol2013;85:612-22

[83] Charles N.The perivascular niche microenvironment in brain tumor progression..Cell Cycle2010;9:3012-21 PMCID:PMC3040926

[84] Scheller J.Interleukin-6 and its receptor: from bench to bedside..Med Microbiol Immunol2006;195:173-83

[85] Trikha M,Klein B.Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence..Clin Cancer Res2003;9:4653-65

[86] Guo Y,Lu T,Zhang Z.Interleukin-6 signaling pathway in targeted therapy for cancer..Cancer Treat Rev2012;38:904-10

[87] Ginestier C,Diebel ME,Luo M,Wicinski J,Charafe-Jauffret E,Guan JL,Wicha MS.CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts..J Clin Invest2010;120:485-97 PMCID:PMC2810075

[88] Hartman ZC,den Hollander P,Hill J,Zhang Y,Hilsenbeck SG,Brown PH.Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8..Cancer Res2013;73:3470-80 PMCID:PMC3853111

[89] Burroughs SK,Wang D,Van Meir EG.Hypoxia inducible factor pathway inhibitors as anticancer therapeutics..Future Med Chem2013;5:553-72 PMCID:PMC3871878

[90] Batchelor TT,di Tomaso E,Plotkin SR,Eichler AF,Hochberg FH,Louis DN,Chea H,Loeffler JS,Ivy P,Wen PY.Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma..J Clin Oncol2010;28:2817-23 PMCID:PMC2903316

[91] Pan E,Yue B,Chowdhary S,Chamberlain M.A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma..J Neurooncol2012;110:111-8 PMCID:PMC5735835

[92] Brossa A,Mancuso L,Satolli MA,Camussi G.Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation..Oncotarget2015;6:11295-309 PMCID:PMC4484457

[93] Garcia A.Bevacizumab and ovarian cancer..Ther Adv Med Oncol2013;5:133-41 PMCID:PMC3556875

[94] Krishnamurthy S,Yang YY.Delivery of therapeutics using nanocarriers for targeting cancer cells and cancer stem cells..Nanomedicine (Lond)2015;10:143-60

[95] Gupta PB,Jiang G,Kuperwasser C,Lander ES.Identification of selective inhibitors of cancer stem cells by high-throughput screening..Cell2009;138:645-59 PMCID:PMC4892125

[96] Malhi S.Nanocarrier-mediated drugs targeting cancer stem cells: an emerging delivery approach..Expert Opin Drug Deliv2015;12:1177-201

[97] Shen S,Wang J.Nanomedicine-mediated cancer stem cell therapy..Biomaterials2016;74:1-18

[98] Zhao Y,Kabanov AV.Can nanomedicines kill cancer stem cells?.Adv Drug Deliv Rev2013;65:1763-83

[99] Bertrand N,Xu X,Farokhzad OC.Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology..Adv Drug Deliv Rev2014;66:2-25 PMCID:PMC4219254

[100] Liu Y,Wang P.Advances and challenges in the use of nanoparticles to optimize PK/PD interactions of combined anti-cancer therapies..Curr Drug Metab2014;15:818-28

[101] Swaminathan SK,Toti U,Ohlfest JR.CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer..J Control Release2013;171:280-7

[102] Vinogradov S.Cancer stem cells and drug resistance: the potential of nanomedicine..Nanomedicine (Lond)2012;7:597-615 PMCID:PMC3376090

[103] Xiao H,Qi R,Wang R,Zheng Y,Huang Y.Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy..J Control Release2012;163:304-14

[104] Kim YJ,Li S,Zhang R,Wang P.Co-Eradication of Breast Cancer Cells and Cancer Stem Cells by Cross-Linked Multilamellar Liposomes Enhances Tumor Treatment..Mol Pharm2015;12:2811-22

[105] Oak PS,Thakur C,Rapp UR,Wagner E,Roidl A.Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells..Int J Cancer2012;131:2808-19